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Amniotic ﬂuid (AF) and amniotic membrane (AM) have been recently characterized as promising sources of stem or progenitor
cells.Bothnotonlycontainsubpopulationswithstemcellcharacteristicsresemblingtoadultstemcells,suchasmesenchymalstem
cells, but also exhibit some embryonic stem cell properties like (i) expression of pluripotency markers, (ii) high expansion in vitro,
or (iii) multilineage diﬀerentiation capacity. Recent eﬀorts have been focused on the isolation and the detailed characterization of
these stem cell types. However, variations in their phenotype, their heterogeneity described by diﬀerent groups, and the absence
of a single marker expressed only in these cells may prevent the isolation of a pure homogeneous stem cell population from these
sources and their potential use of these cells in therapeutic applications. In this paper, we aim to summarize the recent progress in
markerdiscoveryforstemcellsderivedfromfetalsourcessuchasAFandAM,usingnovelmethodologiesbasedontranscriptomics,
proteomics, or secretome analyses.
1.Introduction
Both amniotic ﬂuid (AF) and amniotic membrane (AM)
represent rich sources of stem cells that can be used in the
future for clinical therapeutic applications. Ethical concerns
regarding the isolation of stem cells from these sources are
minimized [1–3], in contrary to the issues emerging from
human embryonic stem cell (ESC) research [4–6]. AF is
collected during scheduled amniocenteses between 15th and
19th week of gestation for prenatal diagnosis and the excess
of sample can be used for cell sourcing [2, 4–9], whereas
AM is usually collected during the caesarean sections of term
pregnancies [10, 11]. Given the heterogeneity of the stem cell
populations derived from these sources, the isolation of spe-
c i ﬁ cc e l lt y p e si sd i ﬃcult and requires a detailed phenotypic
andmolecularcharacterizationoftherespectivecells.Studies
that include omics approaches are fundamental in better
understanding the mechanisms of molecular expression of
these cells and deﬁning the correct methodologies for their
isolation, prior to their use in therapeutic approaches.
This paper aims to present the main biological and
molecular characteristics of AF- and AM-derived stem cells
and also to highlight the recent advances in marker discovery
using global methodologies, such as transcriptomics, pro-
teomics, or secretome analyses.
1.1. Amniotic Fluid. AF serves as a protective liquid for the
developing embryo, providing mechanical support and the
required nutrients during embryogenesis [1, 3]. Amniocen-
tesis has been used for many decades as a routine procedure
for fetal karyotyping and prenatal diagnosis, allowing the
detection of a variety of genetic diseases [1, 3, 12].
The major component of AF is water; however its
overall composition varies throughout pregnancy. At the
beginning of pregnancy, the amniotic osmolarity is similar
to the fetal plasma. After keratinization of the fetal skin
amniotic osmolarity decreases relatively to maternal or fetal
plasma, mainly due to the inﬂow of fetal urine [1]. More
interestingly, AF also represents a rich source of a stem cell
population deriving from either the fetus or the surrounding2 Stem Cells International
amniotic membrane [1, 12]. Additional investigations by
several groups have been recently focused on the cellular
properties of amniotic derived cells and their potential use in
preclinical models [13–18] and in transplantation therapies
[7, 17, 19–24].
1.1.1. Amniotic Fluid Stem Cells (AFSCs). The amniotic ﬂuid
cells (AFCs) represent a heterogeneous population derived
from the three germ layers. These cells share an epithelial
origin and are derived from either the developing embryo or
the inner surface of the amniotic membrane, which are
characterized as amniotic membrane stem cells [12]. The
AFCs are mainly composed of three groups of adherent
cells, categorized based on their morphological, growth, and
biochemical characteristics [12]. Epithelioid (E-type) cell are
cuboidal to columnar cells derived from the fetal skin and
urine, amniotic ﬂuid (AF-type) cells are originating from
fetalmembranes,andﬁbroblastic(F-type)cellsaregenerated
mainly from ﬁbrous connective tissue. Both AF- and F-type
cells share a ﬁbroblastoid morphology and the dominant
cell type appears to be the AF-type, coexpressing keratins
and vimentins [1–3, 8, 9, 25–27]. Several studies have
documented that human amniotic ﬂuid stem cells (AFSCs)
can be easily obtained from a small amount of second
trimester AF, collected during routine amniocenteses [2, 4–
9], a procedure with spontaneous abortion rate ranging
from 0.06 to 0.5% [2, 28, 29] .U pt od a t e ,an u m b e ro f
diﬀerent cultivation protocols have been reported, leading
to enriched stem cell populations. The isolation of AFSC
and the respective culture protocols were summarized in a
recent review by Klemmt et al. [3] and can be categorized
as follows: (i) a single step cultivation protocol, where the
primary culture was left undisturbed for 7 days or more
until the ﬁrst colonies appear [2, 3, 30–32], (ii) a two-step
cultivation protocol, where amniocytes, not attached after
5 days in culture, were collected and further expanded [3,
5, 33], (iii) cell surface marker selection for CD117 (c-kit
receptor) [3, 7, 34, 35], (iv) mechanical isolation of the
initial mesenchymal progenitor cell colonies formed in the
initial cultures [9], and (v) short-term cultures to isolate
ﬁbroblastoid colonies [36]. The majority of the AFSCs,
isolatedfollowingthesemethodologies,sharedamultipotent
mesenchymal phenotype and exhibited higher proliferation
potential and a wider diﬀerentiation potential compared to
adult MSCs [2, 4–7, 9, 24, 37].
1.2. Amniotic Membrane (AM). The amniotic membrane,
lacking any vascular tissue, forms most of the inner layer of
the fetal membrane [12, 38] and is composed of 3 layers:
(i) an epithelial monolayer consisting of epithelial cells, (ii)
an acellular intermediate basement layer, and (iii) an outer
mesenchymal cell layer, rich in mesenchymal stem cells and
placed in close proximity to the chorion [12, 38]. AM was
used in clinic for many decades for wound healing in burns,
promoting epithelium formation and protecting against
infection[39,40].R ecently ,theuseofAMhasbeenevaluated
as a wound dressing material for surgical defects of the oral
mucosa [41], ocular surface reconstruction [40, 42], corneal
perforations [43, 44], and bladder augmentation [45].
1.2.1. Amniotic Membrane Stem Cells (AMSCs). Amniotic
membrane stem cells (AMSCs) include two types, the amni-
otic epithelial cells(AECs) andtheamniotic membranemes-
enchymal stem cells (AM-MSCs) derived from the amniotic
epithelial and the amniotic mesenchymal layers, respectively
[12, 46]. Both cell types are originated during the pregastru-
lationstagesofthedevelopingembryo,beforethedelineation
of the three primary germ layers and are mostly of epithelial
nature [38, 47]. A variety of protocols have been established
for AECs and AM-MSCs isolation, primarily based on
the mechanical separation of the AM from the chorionic
membrane and the subsequent enzymatic digestion [47–
50]. AM-MSCs exhibited plastic adherence and ﬁbroblastoid
morphology, while AECs displayed a cobblestone epithelial
phenotype. AM-MSCs shared similar phenotypic charac-
teristics with the ones derived from adult sources. More
interestingly, AM-MSCs, similarly to AF-MSCs, exhibited a
higher proliferation rate compared to MSCs derived from
adult sources [12, 51] and a multilineage diﬀerentiation
potential into cells derived from the three germ layers [27].
2. Immunophenotype
2.1. Amniotic Fluid Stem Cells. The AF has recently emerged
as an alternative fetal source of a variety of cells of stem
cell origin [1, 3]. Herein, we aim to summarize the key
markers that characterize AFSCs. To date, MSCs represent
the best characterized subpopulation of AFSCs. The AF-
MSCs exhibited typical mesenchymal marker expression,
such as CD90, CD73, CD105, CD29, CD166, CD49e, CD58,
and CD44, determined by ﬂow cytometry analyses [2, 5–
8, 10, 12, 21, 32, 33, 52, 53]. Additionally, these cells
expressed the HLA-ABC antigens, whereas the expression of
the hematopoietic markers CD34 and CD45, the endothelial
marker CD31, and the HLA-DR antigen was undetected
[2, 5, 6, 32]. More importantly, the majority of cultured AF-
MSCs expressed pluripotency markers such as the octamer
binding protein 3/4 (Oct-3/4), the homebox transcription
factor Nanog (Nanog), and the stage-speciﬁc embryonic
antigen 4 (SSEA-4) [2, 5–7, 9, 21, 32, 33, 52].
It was also reported that amniocyte cultures contain a
small population of CD117 (a tyrosine kinase speciﬁc for
stem cell factor present primarily in ESCs and primordial
germcells)positivecellsthatcanbeclonallyexpandedincul-
ture [7]. The diﬀerentiation properties of CD117+ AFS were
tested for the ﬁrst time in vivo, proving in this way their stem
cellidentity[7].ExperimentalevidencesuggestedthatAFSCs
are derived from spindle-shaped ﬁbroblastoid cells [10].
In an attempt to analyze the AFSCs subpopulations,
our group recently identiﬁed two morphologically distinct
populations of AFSCs of mesenchymal origin, with diﬀerent
proliferation and diﬀerentiation properties, termed as
spindle shaped (SS) and round shaped (RS) [9]. Both
subpopulations were expressing mesenchymal stem cell
markers at similar levels. However, it was identiﬁed that SSStem Cells International 3
colonies expressed higher levels of CD90 and CD44 antigens
compared to RS colonies [9].
2.2. Amniotic Membrane Stem Cells (AMSCs). A detailed
immunophenotype analysis of AMSCs revealed the expres-
sion of antigens, such as CD13, CD29, CD44, CD49e, CD54,
CD73, CD90, CD105, CD117low, CD166, CD27low,s t r o m a l
stem cell marker 1 (Stro-1), SSEA-3, SSEA-4, collagen I and
III(Col1/Col3),alpha-smoothmuscleactin(α-SMA),CD44,
vimentin (Vim), ﬁbroblast surface protein (FSP), and HLA-
ABC antigen [10, 12, 27]. However, intercellular adhesion
molecule 1 (ICAM-1) was expressed in very low levels and
proteins TRA-1-60, vascular cell adhesion protein 1 (VCAM-
1), von Willebrand factor (vWF), platelet endothelial cell
adhesion molecule (PECAM-1), CD3, and HLA-DR were
not detected [10, 27]. One of the most abundant proteins
found in AM derived cells is laminin, which plays a key
role in diﬀerentiation, cell shape and migration, and tissue
regeneration [54, 55]. RT-PCR analysis further showed
that AMSCs expressed genes, such as Oct-3/4, zinc ﬁnger
p r o t e i n4 2( z f p 4 2o rR e x - 1 ) ,s t e mc e l lf a c t o rp r o t e i n( S C F ) ,
neural cell adhesion molecule (NCAM), nestin (NES), bone
morphogenetic protein 4 (BMP-4), GATA binding protein
4 (GATA-4), and hepatocyte nuclear factor 4α (HNF-4α)
even in high passages. Brachyury, ﬁbroblast growth factor
5 (FGF5), paired box protein (Pax-6), and bone morpho-
genetic protein 2 (BMP2) transcripts were not detected [10,
12]. Similarly, AECs were positive for CD10, CD13, CD29,
CD44, CD49e, CD73, CD90, CD105, CD117, CD166, Stro-
1,HLA-ABC,andHLA-DQlow andnegativeforCD14,CD34,
CD45, CD49d, and HLA-DR expressions, as determined by
FACS analyses [27, 47–50]. Further investigation showed
that AECs were expressing stem cell markers such as SSEA-
1, SSEA-3, SSEA-4, Nanog, sex determining region Y-box
2 (Sox2), Tra1-60 and Tra1-80, ﬁbroblast growth factor 4
(FGF4), Rex-1, cryptic protein (CFC-1), and prominin 1
(PROM-1) [38, 50].
3.Transcriptomics
3.1. Amniotic Fluid Stem Cells. A functional analysis of the
gene expression signature of AF-MSCs compared to bone-
marrow- (BM-), cord-blood- (CB-), and AM-MSCs was
initially performed by Tsai et al. [11]. Genes expressed in
MSCs from all three sources could be categorized in groups
related to (i) extracellular matrix remodeling (CD44, colla-
genII(COL2),insulin-likegrowthfactor2(IGF2),andtissue
inhibitor of metalloproteinase 1 (TIMP1)), (ii) cytoskeletal
regulation (urokinase-type plasminogen activator (PLAU)
and receptor (PLAUR)), (iii) chemokine regulation and
adhesion (alpha actinin 1 (ACTN1), actin-related protein
complex subunit 1B (ARPC1B) and thrombospondin 1
(THBS1)), (iv) plasmin activation (tissue factor pathway
inhibitor 2 (TFPI2)), (v) transforming growth factor β
(TGFβ) receptor signaling (caveolin 1 (Cav1), caveolin 2
(Cav2), cyclin-dependent kinase inhibitor 1A (CDKN1A)),
and (vi) genes encoding E3 ubiquitin ligases (SMURF) [11].
The upregulated genes in AF-MSCs compared to BM-, CB-,
and AM-MSCs included molecules involved in uterine mat-
uration and contraction, such as oxytocin receptor (OXTR)
and regulation of prostaglandin synthesis, such as phospho-
lipase A2 (PLA2G10). Other upregulated genes in this group
were involved in signal transduction related to (i) thrombin
triggeredresponse((F2RandF2RL)),(ii)hedgehogsignaling
((hedgehog acyltransferase (HHAT)), and (iii) G-protein-
relatedpathways(rho-relatedGTP-binding protein(RHOF),
regulator of G protein signaling 5 and 7 (RGS5, RGS7), and
phospholipase C beta 4 (PLCB4)) [11].
In recent studies on AFSCs, Kim et al. described for the
ﬁrst time the gene expression changes in total AFSC popula-
tion during diﬀerent passages by illumina microarray analy-
sis. 1970 diﬀerentially expressed genes were detected and cat-
egorized according to their expression proﬁles into 9 distinct
clusters [56]. Genes with gradually increasing expression lev-
els included chemokine (C-X-C motif) ligand 12 (CXCL12),
cadherin 6 (CDH6), and folate receptor 3 (FOLR3). Down-
regulatedgeneswereamongothers,cyclinD2(CCND2),ker-
atin8(K8),IGF2,natriureticpeptideprecursor(BNP)B,and
cellular retinoic acid binding protein 2 (CRABPII) [56]. To
obtainfurtherinformation,chipdataanalysisonaginggenes
wasperformedandrevealedupregulationofgenetranscripts,
such as nerve growth factor beta (NGFβ), insulin receptor
substrate 2 (IRS-2), insulin-like growth factor binding pro-
tein 3 (IGFBP-3), and apolipoprotein E (APOE). Expression
of genes, such as PLAU, E2F transcription factor 1 (E2F1),
IGF2,breastcancertype1susceptibilitygene(BRCA1),DNA
topoisomerase 2-alpha (TOP2A), proliferating cell nuclear
antigen (PCNA), forkhead box M1 (FOXM1), cyclin-A2
gene (CCNA2), budding uninhibited by benzimidazoles 1
homolog beta (BUB1B), and cyclin dependent kinase 1
(CDC2), was gradually downregulated during culture [56].
Wolfrum et al. performed a global gene expression analy-
sis of AFSCs compared to iPSCs derived from AF (AFiPSC)
and ESCs [57]. Among these, genes related to self renewal
and pluripotency (1299 genes e.g., POU class 5 homeobox
1 (POU5F1), Sox2, Nanog, microRNA-binding protein
LIN28) and AFSCs-speciﬁcity (665 genes, e.g., OXTR,
HHAT, RGS5, neuroﬁbromatosis type 2 (NF2), pro-
tectin (CD59), tumor necrosis factor superfamily member
10 (TNFSF10), 5-nucleotidase (NT5E)) were detected in
AFSCs [57]. Furthermore, the authors examined the expres-
sion of senescence and telomere associated genes in AFSCs of
early and later passage, in order to study the eﬀect of repro-
gramming on bypassing senescence observed in AFSC cul-
tures. Sixty-four genes were identiﬁed as diﬀerentially ex-
pressed in AFSCs compared to AFiPSC lines. Of these, telo-
mere-associated genes and genes involved in regulating cell
cycle, such as the mitotic arrest deﬁcient-like 2 (MAD2L2),
the poly ADP-ribose polymerase 1 (PARP1), replication pro-
tein A3 (RPA3), the dyskeratosis congenita 1 (DKC1), the
mutS homolog 6 (MSH6), the CHK1 checkpoint homolog
(CHEK1), the polo-like kinase 1 (PLK1), the POU class 2
homeobox 1 (POU2F1), the CDC2, the Bloom syndrome
gene RecQ helicase-like (BLM), the Werner syndrome
RecQ helicase-like (WRN), the DNA methyltransferase 1
(DNMT1), the DNA methyltransferase 3 beta (DNMT3B),
the lamin B1 (LMNB1), and the DNA replication factor 14 Stem Cells International
(CDT1), were downregulated in AFSCs compared to
AFiPSCs and ESCs. In contrast, peptidylprolyl cis/trans
isomerase (PIN1), lamin A/C (LMNA), growth arrest and
DNA damage inducible alpha (GADD45A), chromobox
homolog 6 (CBX6), NADPH oxidase 4 (NOX4), endoglin
(ENG), histone H2B type 2-E (HIST2H2BE), CDKN1A,
C D K N 2 Ag r o w t hd i ﬀerentiation factor 15 (GDF15), and
serine protease inhibitor 1 (SERPINE1), among others, were
upregulated in AFSCs compared to AFiPSCs and ESCs [57].
3.2. Amniotic Membrane Stem Cells. Transcriptomic analysis
using DNA microarrays has been reported for AM-MSCs
[11]. These experimental data provided information on
the AM-MSC gene expression pattern compared to gene
expression proﬁles of AF, CB, and BM-MSCs. Several upreg-
ulated genes in AM-MSCs involved in immune adaptation
regulation between the maternoplacental interface were
identiﬁed. Among others, spondin 2 (SPON2), interferon,
alpha inducible protein 27 (IFI27), bradykinin receptor B1
(BDKRB1), small inducible cytokine subfamily B member
5 and 6 (SCYB5, SCYB6), and Yamaguchi sarcoma viral-
related oncogene homolog (LYN) were found to be upregu-
lated [11]. In addition, other genes with increased expression
in AM-MSCs compared to AF, CB, and BM-MSCs included
(i) transcription factors, such as forkhead box F1 (FOXF1),
heart and neural crest derivatives expressed 2 (HAND2),
and transcription factor 21 (TCF21) and (ii) metabolic
enzymes, such as dipeptidyl-peptidase 6 (DPP6), tryptophan
2,3-dioxygenase (TDO2), and sialyltransferases (STs) [11].
4. Proteomics
4.1.AmnioticFluidStemCells. Proteomicstudiesonthetotal
AFSC population, including epithelioid (E-type), amniotic
ﬂuid speciﬁc (AF-type), and ﬁbroblastic (F-type) cells,
revealed 2400 spots that resulted in the identiﬁcation of 432
diﬀerent gene products. The majority of the proteins was
localized in cytoplasm (33%), mitochondria (16%), and
nucleus (15%) and represented mainly enzymes (174 pro-
teins) and structural proteins (75 proteins). A relatively high
percentage of membrane and membrane-associated proteins
were also present (7%) [58]. Among the detected proteins,
9 were corresponding to epithelial cells, such as ATP syn-
thase D chain (ATP5H), NADH-ubiquinone oxidoreductase
30kDa subunit (NUIM), annexin II (Anx2), annexin IV
(Anx4), 40S ribosomal protein SA (Rpsa), glutathione S-
transferase P (GSTP), major vault protein, and cytokeratins
19 and 7 (CK-19, CK-7), whereas 12 proteins were reported
to be expressed in ﬁbroblasts, including ﬁbronectins, tropo-
myosins, transgelin (TAGLN), arp2/3 complex 34kDa sub-
unit (P34-arp), gelsolin (Gsn), elongation factor 1-β (EF-
1β), and others. Eight proteins were found to be expressed in
keratinocytes, including keratins, ribonucleoproteins, Anx2,
aetyl-CoA acetyl-transferase (ACAT1), and others, three to
be expressed in epidermis, including tropomyosins and ker-
atins and one in mesenchymal cell type (vimentin 1 (Vim 1))
[58].
Recent studies provided evidence that a diversity of
metabolic enzyme expression in the amnion cells is involved
in metabolic and genetic syndromes, and thus, their detec-
tion might be important for prenatal diagnosis. A more
detailed analysis for determining speciﬁc metabolic enzymes
p r e s e n ti nA F S C sw a sr e p o rt e db yO he ta l .[ 59]. Ninety-nine
proteins had been identiﬁed, such as carbohydrate handing
enzymes, amino acid handling enzymes, proteins of purine
metabolism, and enzymes of intermediary metabolism [59,
60].
A proteomic analysis was also performed on diﬀerent
culture passages of CD117+ AFSCs, exhibiting variations in
protein expression that mainly occurred in early passages
[35]. Twenty-three proteins were diﬀerentially expressed
between early and late passages with the most sticking
downregulated proteins, the Col1, the Col2, the vinculin
(Vcl), the CRABP II, the stathmin (STMN1), and the coﬁlin-
1 (CFL1). In contrast, TAGLN and Col3 are increased during
passages [35]. Proteins that showed dysregulated levels along
the passages were the 26S protease regulatory subunit 7
(PSMD7), the ubiquitin carboxyl terminal hydrolase isoen-
zyme L1 (UCH-L1), the heterogeneous nuclear ribonuclear
protein H (hnRNP H), and the TAR DNA-binding protein
43 (TDP-43) [35].
In 2007, the proteomic map of human AF-MSCs was
constructed and directly compared to the one derived from
BM-MSCs [2]. 261 diﬀerent proteins were identiﬁed in
AF-MSCs with the majority of the proteins localized in
the cytoplasm (41%), whereas others were found in the
endoplasmic reticulum (8%), nucleus (13%), mitochondria
(12%), ribosomes (1%), cytoskeleton (6%), cytoplasm and
t h en u c l e u s( 5 % ) ,a n ds e c r e t e d( 2 % )p r o t e i n s[ 2]. AF-MSCs
expressed a number of proteins related to proliferation and
cell maintenance, such as ubiquilin-1 (UBQLN1), which is
known to control cell cycle progression and cell growth,
the proliferation associated protein 2G4 (PA2G4), a nucle-
olar growth-regulating protein, the secreted protein acidic
and rich in cysteine (SPARC), which is regulated during
embryogenesis and is involved in the control of the cell
cycle and cell adhesion, and the enhancer of rudimentary
homolog (ERH) that also regulates cell cycle [2]. TAGLN
and galectin 1 (Gal 1), both present in stem cells and
related to diﬀerentiation, were also abundantly expressed in
AF-MSCs. Other proteins expressed in high levels in AF-
MSCs were related to (i) development, such as Deltex-3-like
(DTX3L), and (ii) cytoskeletal organization and movement,
such as CFL1, the coactosin-like protein (CLP), and the
enabled protein homolog (Enah). As expected, Vim was also
expressed in high amounts in AF-MSCs. In this study, a
detailed comparison of the common identiﬁed proteins in
AF cells [58] and AF-MSCs was also described [2].
In our later study [9], we established the proteomic
map of the two morphologically distinct AF mesenchy-
mal progenitor cell types (SS and RS) by 2-DE. Twenty-
ﬁve proteins were diﬀerentially expressed in the two sub-
populations. Proteins upregulated in SS-AF-MSCs com-
pared to RS-AF-MSCs included reticulocalbin-3 precursor
(RCN3), collagen α1( I )( C O L 1 α1), FK506-binding protein
9 precursor (FKBP9), Rho GDP-dissociation inhibitor 1
(RhoGDI), chloride intracellular channel protein 4 (CLIC4),
tryptophanyl-tRNA synthetase (TrpRS), and 70kD heatStem Cells International 5
shock protein (HSP70). Peroxiredoxin 2 (Prdx2), 60kD heat
shockprotein(HSP60),GSTP,andAnx4wereupregulatedin
RS-AFMPCs. However, proteins identiﬁed in RS-AF-MSCs
only included cytokeratin-8, -18, and -19 (CK-8, -18, and
CK-19), cathepsin B (CTSB), CLP, and integrin αVp r o t e i n
( C D 5 1 ) .M e s e n c h y m a l - r e l a t e dp r o t e i n s ,s u c ha sV i m ,G a l ,
Gsn, and prohibitin (PHB), were expressed at the same levels
in both populations [9].
4.2. Amniotic Membrane Stem Cells. A detailed approach for
studying human AM proteins was described by Hopkinson
et al. [61]. In this study, the authors performed a proteomic
analysis of AM samples that were prepared for human trans-
plantation, by using 2-DE gels. The wash media from the
AM samples were also examined and the secreted proteins
were identiﬁed. Proteins detected in both AM and the wash
media suggested that partial protein release had occurred.
These proteins were mostly soluble cytoplasmic proteins and
were categorized according to their subcellular localization
and function [61]. One example of the most abundant and
consistentproteinsinAMisTHBS1whichisreportedtoplay
role in wound repair, inﬂammatory response, and angio-
genesis [62, 63]. Mimecan (also named osteoglycin/OGN)
is another protein detected in AM that represents a small
leucine-rich proteoglycan, found in the ECM of connective
tissue. Mimecan is reported to maintain the tensile strength
and hydration of the tissue [61, 64–66]. In addition, the
larger form of mimecan was expressed in AM cells and
was susceptible to proteolytic cleavage [65]. TGF-β-induced
protein ig-h3 (βIG-H3), an ECM adhesive molecule acting
as a membrane-associated growth factor during cell diﬀer-
entiation and wound healing, and intergrin α6 (CD49f), a
component of α6β4 integrin, were also present in signiﬁcant
amounts in AM cells [61, 67, 68]. It is well known that α6β4-
βIG-H3 interaction plays an important role in mediating cell
adhesion and wound repair signaling pathways [69].
Another important study by Baharvand et al. [70]w a s
focused on the analysis of epithelium-denuded human
AM showing both quantitative and qualitative diﬀerences
compared to nontreated AM [61]. They investigated the
proteome of the human AM epithelium, which was used as a
limbal stem cell niche for treating ocular surface reconstruc-
tion [71, 72]. 515 spots were detected in all the 2-DE gels
and 43 proteins were identiﬁed using MALDI TOF/TOF MS
in AM. The most abundant proteins were diﬀerent isoforms
o fl u m i c a n( L U M )a n dO G N ,b o t hm e m b e r so ft h ep r o -
teoglycan (PG) family. In particular, OGN might play role in
many biological processes including cell growth, angiogene-
sis, and inﬂammation [66]. Other proteins detected included
collagen VI α-1/α-2 (Col6a1/Col6a2), ﬁbrinogen beta chain
(FGB), transglutaminase 2 isoform A (TGM2A), b-actin
variant (ACTB), 70kD heat shock protein 5 (HSPA5),
nidogen 2 (NID2), CD49f, βIG-H3, and tubulointerstitial
nephritis (TIN) [70]. Some of the proteins identiﬁed in this
study were also related to extracellular matrix (ECM).
Among the detected ones, ﬁbronectin (FN), laminins,
a n dc o l l a g e nI V( C o l 4 )a n dV I Iw e r er e p o r t e dt op r o m o t e
epithelial adhesion and migration [73, 74].
5.Secretome
Recently, signiﬁcant progress has been made regarding the
analysisofthesecretedproteinsfromAFSCs.Ithasbeendoc-
umentedthatAFSCsecretomewasresponsibleforenhancing
vasculogenesis and was capable of evoking a strong angio-
genic response in murine recipients [75]. According to this
study, a detailed analysis of the AFSC-conditioned media
revealed the presence of known proangiogenic and antian-
giogenic factors using Luminex’s MAP Technology. Vascular
endothelial growth factor (VEGF), stromal cell-derived
factor 1 (SDF-1), interleukin 8 (IL-8), monocyte chemo-
tactic protein 1 (MCP-1), and two angiogenesis inhibitors,
interferon-gamma (IFNγ) and interferon gamma-induced
protein 10 (IP-10), were identiﬁed as secreted proteins [75–
77]. It was also demonstrated that a relative small number
of AFSC was enough to secrete a detectable amount of
proangiogenic growth factors and cytokines. The secretion
of these can be regulated in a dose-dependent manner
according to the initial cell number of the cells used [24, 75].
A systematic study on AFSC-secreted proteins led to the
conclusion that proangiogenic soluble factors from AFSCs
can mediate the recruitment of endothelial progenitors in an
ischemic rat model [78]. In particular, conditioned medium
derived from AFSCs could topically deliver angiogenic
growth factors and cytokines into the skin ﬂap of the
ischemic rat model and was responsible for triggering the
endogenous repair by recruiting endothelial progenitor cells
[78].
In our recent studies, we examined the therapeutic
potential of an AF-MSCs and their secreted molecules in
mice with acute hepatic failure [24]. A variety of cytokines
and growth factor were detected in AF-MSC conditioned
medium. Cytokines such as interleukin 10 (IL-10), inter-
leukin 27 (IL-27), interleukin 17 family (IL-17E), interleukin
12p70 (IL-12p70), interleukin-1 beta (IL-1β), and interleuk-
in-1 receptor antagonist (IL-1ra), responsible for inducing
local and systemic downregulation of pro-inﬂammatory
mediators, were detected. SERPINE1, MCP-1, and SDF-1,
responsible for promoting tissue repair, were also secreted
[24, 79, 80]. Interestingly, among the highly expressed
growth factors were platelet-derived endothelial cell growth
factor (PD-ECGF), endostatin/collagen XVII (EN/Col17),
urinary plasminogen activator (uPA), TIMP1, TIMP2,
heparin-binding EGF-like growth factor (HB-EGF), ﬁbro-
blast growth factor 7 (FGF7), and epidermal growth factor
(EGF), responsible for liver regeneration and tissue repair
[24, 81].
6. Summary
The current data so far suggest that amniotic ﬂuid and
amniotic membrane may represent promising sources for
stem cells of mesenchymal origin. Indeed, MSCs are more
abundant and a wide range of protocols has been described
for their isolation. However, it is reported that diﬀerent cul-
ture conditions of the same type of cells may aﬀect their
diﬀerential gene expression pattern, which represents a
limitation for their isolation and expansion in vitro. Studies6 Stem Cells International
Transcriptomics
Proteomics
Secretome
Immunophenotype
AFSCs:
AFSCs:
------------------------------------
AFSCs:
AFSCs: 
IGF2, PLAU, OXTR, HHAT,
CD44, COL2, TIMP1, ACT1,
Cav1, Cav2, CDKN1A,
SMURF, F2R, F2RL, IL7R,
RHOF, RGS7 [11],
CXCL12, CDH6, FOLR3,
CCND2, K8, CRABPII, NGFB,
IRS2, APOE, IGFBP3, E2F1,
TOP2A, FOXM1, BUBB1 [56],
Nanog, Sox2, POU5F1, NF2,
CD59, NTSE, MAD2L2,
PARP1, RPA3, DKC1, MSH6,
PLK1, CHEK1, BLM, WRN,
CDT1, PIN1, DNMT1,
DNMT3B, LMNB1, LMNA,
CDKN2A, GADD45A, GDF15,
SERPINE 1 [57]
ARPC1B, TSP1, TFRI2, TGFβ,
AMSCs:
SPON2, IFI27, BDBKRB1, 
SCYB5,
DPP6, TDO2, STs [11]
SCYB6, FOXF1,
HAND2, TCF21,
TAGLN [2, 34, 58], Gsn,
Anx4, GSTP, CK-19 [9, 58],
Col1 [9, 34], Gal, CLP [2, 9],
Anx2, Rpsa , ATP5H, CK-7,
EF-1β, ACAT1, P34-arp,
NUIM [58],
Col2, Col3, VCL, CRABPII,
STMN1, PSMD7, UCH-L1,
hnRNPH, TDP43 [34],
UBQLN1, PA2GA,
SPARC, ERH, DTXEL,
Enah [2],
RCN3, FKBP9, CLIC4,
HSP60, HSP70, Prdx2,
RhoGDI, CTSB, CD51,
CK-8, CK-18 [9]
AMSCs:
OGN, βIG-H3, CD49F [61, 70], THBS1 [61],
LUM, COL, TGM2A, ACTB, FGB, NID2, HSPA5 [70]
SDF-1, MCP-1 [75, 23],
VEGF, IFNγ, IP-10,
IL-8 [70],
SERPINE 1, PD-
ECGF, FGF7, HB-
EGF, EGF, TIMP1,
TIMP2, uPA, EN,
Col17, IL-10, IL-27,
IL-1β, IL-1ra, IL-
12p70, IL-17E [23]
AMSCs:
CD13, CD29, CD44, CD49e, CD73, CD90,
PROM1 [37, 49],
[10, 12, 50]
CD90, CD73, CD105, CD29, CD166, CD49e,
31, 32, 52, 53], CD117 [7]
RCS5 [11, 57], CDC2 [56, 57],
Vim [2, 9, 53], CFL1 [2, 34],
CD105, CD117, CD166, Stro-1, HLA-ABC,
SSEA-3, SSEA-4, Rex-1 [10,12, 37, 46–50],
Nanog , Sox2, Tra1-60, Tra1-80, FGF-4, CFC-1,
CD10, HLA-DQ [46–50]
CD27, Col1, Col3, α-SMA, Vim, FSP, Oct-3/4,
SCF, NCAM, NES, BMP-4, GATA-4, HNF-4α
CD58, CD44, HLA-ABC, SSEA-4 [2, 58, 10, 12, 24,
Figure 1: Summary of the most important markers identiﬁed in AFCs and AMCs by the use of transcriptomics, proteomics, secretome, and
immunophenotypic analyses. Proteins identiﬁed in more than one study are marked in bold.
including phenotypic analysis, using methodologies such as
ﬂow cytometry and immunohistochemistry, as well as tran-
scriptomics,proteomics,andsecretomeanalysesapproaches,
aim to determine the protein proﬁle of these cells (Figure 1).
Data generated by such studies are expected to clarify their
diﬀerential repertoire and validate the molecular proﬁle
of these stem cells. However, the main issue urged to be
addressed is the isolation of a homogenous population that
may facilitate systematic studies for the elucidation of the
function of these multipotent cells.
Such approaches may lead to the identiﬁcation of key
antigens that mirror the phenotype of these cells and explain
their distinct features properties. This type of studies will
o p e nt h ew a yf o ras y s t e m a t i ca n de ﬃcient isolation of these
cells prior to their use at the clinical setting.
Appendix
Questions for Further Investigation
Which are the appropriate isolation methods and culture
conditions of AFSCs or AMSCs that will allow the identiﬁ-
cation of a consistent phenotype?
Is there a single marker that can be used for AFSCs or
AMSCs isolation?
TheAFSCandAMSCpopulationsareheterogeneousand
diﬀerintheirphenotypicandmolecularproperties.Methods
of isolation can result in a homogeneous cell population.
AFSCs or AMSCs can be used as tools in regenerative
medicine: establishment of culture conditions with minimal
or no animal substances.
Marker Discovery. The AFSCs and the AMSCs initial charac-
terization can be performed by immunophenotype analysis
by using well-characterized cell surface markers such as
AFSCs: CD90, CD73, CD105, CD29, CD166, CD49e, CD58,
CD44, HLA-ABC, SSEA-4; AMSCs: CD13, CD29, CD44,
CD49e, CD73, CD90, CD105, CD117, CD166, Stro-1, HLA-
ABC, SSEA-3, SSEA-4, Nanog, Sox2, Tra1-60, Tra1-80, FGF-
4, CFC-1, and PROM1.
Transcriptomics and Proteomics Revealed the Identiﬁcation
of Key Markers Expressed such as. AFSCs: Nanog, Sox2,
POU5F1, NF2, IGF2, PLAU, OXTR, HHAT, RCS5, CDC2,
C O L 2 ,T A G L N ,G s n ,A n x 4 ,G S T P ,C K - 1 9 ,V i m ,C o l 1 ,a n d
Gal; AMSCs: OGN, βIG-H3, and CD49F.Stem Cells International 7
Since there is no common marker available for AFSC
and AMSC, a wider panel of markers needs to be employed.
This also urges the conduction of further detailed array and
functional analyses in order to deﬁne the most appropriate
markers for AFSC and AMSC characterization.
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